452 related articles for article (PubMed ID: 34079368)
21. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
22. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Paracha N; Reyes A; Diéras V; Krop I; Pivot X; Urruticoechea A
Breast Cancer Res Treat; 2020 Apr; 180(3):597-609. PubMed ID: 32100144
[TBL] [Abstract][Full Text] [Related]
23. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
[TBL] [Abstract][Full Text] [Related]
24. Systemic management of brain metastases in HER2+ breast cancer in 2022.
Alder L; Sammons S; Van Swearingen AED; Anders CK
Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
[TBL] [Abstract][Full Text] [Related]
25. Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF; Bruni S; Mauro FL; Schillaci R
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046648
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
Barginear MF; John V; Budman DR
Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
[TBL] [Abstract][Full Text] [Related]
27. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.
Sadeghi S; Olevsky O; Hurvitz SA
Pharmgenomics Pers Med; 2014; 7():329-38. PubMed ID: 25378946
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
29. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer.
Bartsch R
Memo; 2021; 14(3):247-251. PubMed ID: 34221179
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
31. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
32. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
34. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
36. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Schettini F; Conte B; Buono G; De Placido P; Parola S; Griguolo G; Fabi A; Bighin C; Riccardi F; Cianniello D; De Laurentiis M; Puglisi F; Pelizzari G; Bonotto M; Russo S; Frassoldati A; Pazzola A; Montemurro F; Lambertini M; Guarneri V; Cognetti F; Locci M; Generali D; Conte P; De Placido S; Giuliano M; Arpino G; Del Mastro L
ESMO Open; 2021 Apr; 6(2):100099. PubMed ID: 33819752
[TBL] [Abstract][Full Text] [Related]
37. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
Ferrario C; Christofides A; Joy AA; Laing K; Gelmon K; Brezden-Masley C
Curr Oncol; 2022 Apr; 29(4):2720-2734. PubMed ID: 35448196
[TBL] [Abstract][Full Text] [Related]
38. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
Due A; Berg T; Jensen MB; Yammeni S; Volmer L; Brems-Eskildsen AS; Andersen KK; Rana S; Knoop A; Kümler I
Acta Oncol; 2023 Feb; 62(2):126-133. PubMed ID: 36929759
[TBL] [Abstract][Full Text] [Related]
39. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
40. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]